Does Hypertension History in Patients with Advanced Gastric Cancer Has an Impact on Clinical Outcomes Following Apatinib Treatment? A Subgroup Analysis Based on Data from Ahead-G201 Study.
Tienan Yi,Jin Li,Shukui Qin,Lu Wen,Junsheng Wang,Wenying Deng,Guifang Zhang,Tongfu Jia,Yi Ba,Haijun Zhong,Jianwei Yang,Xiaoyan Lin,Yu-Xian Bai,Yifu He,Zhong Xie,Xiangyuan Wu,Feng Ye,Likun Liu,Yong Huang,Mei Wang
DOI: https://doi.org/10.1200/jco.2018.36.15_suppl.e16022
IF: 45.3
2018-01-01
Journal of Clinical Oncology
Abstract:e16022 Background: Hypertension (HTN) is one of the most common adverse events (AEs) associated with apatinib treatment in gastric carcinoma. However, few studies focus on the effect of HTN history on the safety and efficacy of apatinib treatment in advanced gastric cancer. We used available data from a phase IV study of Ahead-G201 to analyze this issue. Methods: As the cut-off date of Dec 21, 2017, a total of 1468 patients (pts) were enrolled in Ahead-G201 study. Incidence of AEs and clinical efficacy outcomes were compared between pts with HTN history and those without. Results: Among 1468 enrolled pts, 248 were found with HTN history, and 1220 were free of HTN prior to apatinib treatment. Significant differences in age, sex, body mass index, disease duration, and diabetes history were found between pts with HTN history and those without. 166 (66.9%) pts with HTN history were found with drug-related AEs (DRAEs) of all grades, which had no significant difference compared to pts without (742, 60.8%). However, pts with HTN history showed an obviously higher incidence of grade 3-4 DRAEs (35.9 vs. 27.1%, p = 0.0069), DRAEs associated with dose modification (36.7 vs. 29.2%, p = 0.0230), DRAEs associated with dose interruption or discontinuation (9.3 vs. 5.3%, p = 0.0264) and severe AEs (25.8 vs. 18.9%, p = 0.0187) than those without. For efficacy, the median PFS and OS in pts with HTN history were 4.1 (95%CI, 3.0-5.3) and 6.1 (95%CI, 4.8-7.6) mos, in pts without HTN history were 4.1 (95%CI, 3.1-4.6) and 6.6 (95%CI, 5.8-7.2) mos, respectively. There was no significant difference. Multivariate analysis also indicated that HTN history was not significantly associated with either PFS or OS in advanced gastric cancer pts following apatinib treatment. Conclusions: Current results suggested that HTN history may not affect clinical outcomes associated with apatinib treatment in previously treated advanced gastric cancer. However, the presence of HTN history may increase the risk of DRAEs, which indicated that close attention should be paid to these pts during apatinib treatment. Clinical trial information: NCT02426034.